Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03536728 · ClinicalTrials.gov registry record · Phase 1
Oral AMXT 1501 Dicaprate in Combination With DFMO
A Phase 1 study, sponsored by Aminex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT03536728 is a Phase 1 study that has completed, run by Aminex Therapeutics. The registered enrollment target is 56 participants.
The verdict
NCT03536728, a Phase 1 study, has completed, sponsored by Aminex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
A Phase 1 study will be conducted to establish safety and dose level of AMXT 1501 dicaprate alone, and in combination with DFMO, in cancer patients.
Interventions
- DRUG DFMO
- DRUG AMXT1501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2018-06-12 |
| Est. Completion | 2023-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03536728
The ClinicalTrials.gov registry entry for NCT03536728 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aminex Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DFMO is the first listed.
NCT03536728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03536728 about?
NCT03536728 is a clinical study titled "Oral AMXT 1501 Dicaprate in Combination With DFMO". A Phase 1 study will be conducted to establish safety and dose level of AMXT 1501 dicaprate alone, and in combination with DFMO, in cancer patients.
What is the current status of trial NCT03536728?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2018-06-12. Estimated completion is 2023-04-21.
What interventions are being tested in trial NCT03536728?
The interventions under investigation include: DFMO (DRUG), AMXT1501 (DRUG).
Who is sponsoring clinical trial NCT03536728?
This trial is sponsored by Aminex Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.